## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<ol> <li>Name and Address of Reporting Person <sup>*</sup></li> <li>Whelan, Jr. Robert M.</li> </ol>		Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol Annovis Bio, Inc. [ANVS]				
(Last) (First) (Middle) C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 3	_X_ Di		-	on(s) to Issuer 10% Owner Other (specify b	(Check all applica	ble)		
(Street) BERWYN, PA 19312 (City) (State) (Zip)	5. If Ar	nendment, I Il Filed(MM/I	Date 6	6. Individual or Joint/Group Filing(Check Applicable Line)				
	Tab	le I - Non-I	Derivative Secu	urities Benefic	cially Owned			
1.Title of Security (Instr. 4)			Beneficially Owned (Instr. 4)		-	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivati	ve Securities	Beneficiall	y Owned ( <i>e.g.</i>	, puts, calls, w	arrants, options,	convertible secu	urities)	
		tion Date Securities			4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)		
Convertible Note	<u>(1)</u>	<u>(1)</u>	Common Stock	<u>(1)</u>	<u>(1)</u>	D		
Series A-1 Preferred Stock	<u>(2)</u>	<u>(2)</u>	Common Stock	59524	<u>(2)</u>	D		
Stock Option (right to buy)	<u>(3)</u>	4/7/2026	Common Stock	17855	\$0.14	D		
Stock Option (right to buy)	<u>(3)</u>	4/6/2028	Common Stock	7142	\$0.25	D		

## **Explanation of Responses:**

- (1) The Convertible Notes have a maturity date of December 31, 2023. Prior to the maturity date, the Convertible Notes will automatically convert into common stock of Annovis Bio, Inc. ("Annovis") upon an initial public offering ("IPO") of Annovis at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by 80% of the public offering price per share of the IPO as set forth on the cover page of the final prospectus for the IPO.
- (2) Each share of Series A-1 Preferred Stock is convertible into common stock of Annovis and has no expiration date. Upon the closing of the IPO, 83,333 shares of Series A-1 Preferred Stock, along with the aggregate accrued or accumulated and unpaid dividends thereon, will automatically be converted into 59,524 shares of common stock of the Issuer.
- (3) As of the date of this report, all of the shares underlying the options are fully vested and exercisable.

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Whelan, Jr. Robert M.					

C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN, PA 19312	X		
Signatures /s/ Maria Maccecchini Attorney-in-Fact		1/29/2020	

\*\*Signature of Reporting Person

1/29/2020 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.